TG Therapeutics FY2025 EPS Estimate Boosted by HC Wainwright

TG Therapeutics, Inc. (NASDAQ:TGTX) – Analysts at HC Wainwright increased their FY2025 EPS estimates for TG Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. HC Wainwright analyst E. White now forecasts that the biopharmaceutical company will post earnings per share of $1.39 for the year, up from their prior estimate of $1.26. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ FY2026 earnings at $2.27 EPS and FY2027 earnings at $2.86 EPS.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million for the quarter, compared to analysts’ expectations of $100.67 million.

A number of other equities analysts have also recently weighed in on TGTX. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. JPMorgan Chase & Co. lifted their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, TG Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $35.11 on Wednesday. The firm’s 50 day moving average price is $30.86 and its two-hundred day moving average price is $28.33. The stock has a market cap of $5.47 billion, a PE ratio of -351.06 and a beta of 2.30. TG Therapeutics has a 52-week low of $12.93 and a 52-week high of $36.94. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

Insider Activity at TG Therapeutics

In related news, CFO Sean A. Power sold 11,337 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total value of $343,397.73. Following the sale, the chief financial officer now directly owns 670,632 shares of the company’s stock, valued at approximately $20,313,443.28. The trade was a 1.66 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 10.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TG Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Vermillion Wealth Management Inc. acquired a new stake in TG Therapeutics in the 4th quarter valued at $30,000. Quadrant Capital Group LLC increased its stake in TG Therapeutics by 137.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 975 shares during the last quarter. Blue Trust Inc. increased its stake in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 371 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 1,594 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its stake in TG Therapeutics by 460.7% in the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 1,737 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.